Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to Alnylam, Senesco, Alcon, and More


Title: Inhibition of Apoptosis-specific eFI-5A with Antisense Oligonucleotides and siRNA as Anti-inflammatory Therapeutics

Patent Number: 8,754,057

Filed: May 2, 2011

Lead Inventor: John Thompson, Senesco Technologies

Title: Use of miR-30e to Treat Vascular Lesions

Patent Number: 8,754,059

Filed: Aug. 25, 2011

Inventor: Lina Shehadeh, University of Miami

Title: Therapeutic Compositions

Patent Number: 8,754,201

Filed: March 10, 2010

Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals

Title: RNAi-related Inhibition of TNF-alpha Signaling Pathway for Treatment of Ocular Angiogenesis

Patent Number: 8,754,202

Filed: June 27, 2011

Inventor: Jon Chatterton, Alcon

Title: Human microRNAs and Methods for Inhibiting Same

Patent Number: 8,754,203

Filed: May 11, 2012

Lead Inventor: Thomas Tuschl, Rockefeller University

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.